Vor Biopharma Inc. — Investor Relations & Filings
Filings indexed
406
across all filing types
Latest filing
2026-05-13
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases. The company is committed to advancing medicines that target the fundamental drivers of autoimmunity, aiming to move beyond symptom control. Its lead candidate, telitacicept, is designed to silence the signals that allow harmful immune cells to survive. The company's objective is to deliver safer, longer-lasting therapies that address the source of autoimmune conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Vor Biopharma Inc. (0001817229) (Filer) | 2026-05-13 | English | |
| ARS - Vor Biopharma Inc. (0001817229) (Filer) | 2026-04-27 | English | |
| DEF 14A - Vor Biopharma Inc. (0001817229) (Filer) | 2026-04-27 | English | |
| S-8 - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-30 | English | |
| 10-K - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-30 | English | |
| 8-K - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-27 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45589387 | 10-Q - Vor Biopharma Inc. (0001817229) (Filer) | 2026-05-13 | English | ||
| 37614832 | ARS - Vor Biopharma Inc. (0001817229) (Filer) | 2026-04-27 | English | ||
| 37610411 | DEF 14A - Vor Biopharma Inc. (0001817229) (Filer) | 2026-04-27 | English | ||
| 33087931 | S-8 - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-30 | English | ||
| 33087925 | 10-K - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-30 | English | ||
| 33059266 | 8-K - Vor Biopharma Inc. (0001817229) (Filer) | 2026-03-27 | English | ||
| 31849744 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31849722 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31849710 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31849675 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31849758 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 31849771 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 31849716 | S-3 Filing | 2026-01-29 | English | ||
| 13270227 | 8-K | 2026-01-12 | English | ||
| 13270231 | 8-K | 2026-01-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
Vor Biopharma Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33479/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33479 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33479 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33479 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33479}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Vor Biopharma Inc. (id: 33479)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.